Announcement of a seminar by the “Sendai City x Tohoku University Smart Frontier Council Wellness Subcommittee” in relation to the XPRIZE Healthspan, a global longevity competition

As announced on our website on May 13, 2025, we applied to the global longevity competition XPRIZE Healthspan¹⁾ and have been selected as one of the TOP40 (semi-finalists). A semi-final clinical trial²⁾ will be conducted this year, and based on the results, the TOP10 (finalists) will be selected in the second half of 2026. The grand prize winner will then be announced in December 2030 based on the results of the final clinical trial³⁾ over the next four years.

To win the TOP 10 award next year and lead the final clinical trial to success, a seminar and social gathering was held on May 29, 2025 at the Tohoku University Graduate School of Medicine (Medicinal Hub) in Sendai, Miyagi Prefecture, with the theme of cutting-edge longevity research (pharmaceuticals, etc.) as a collaboration between academia, industry, and government to confront the era of super-aging, led by the “Sendai City x Tohoku University Smart Frontier Council* Wellness Subcommittee.”

※ https://sendai-tokku.jp/smart-frontier-sendai/

At the seminar, our Chairman Miyata Toshio, who is also the representative of the XPRIZE Healthspan Tohoku University team and a professor at the Tohoku University Graduate School of Medicine, gave a speech on the theme of “Tohoku University’s Challenge to XPRIZE Healthspan: Toward the Development of a Longevity Medicine.” In addition, Professor Harigae Hideo, Executive Vice President and Hospital Director of Tohoku University, who is the head of the XPRIZE Healthspan clinical trial, and some experts in cognition and locomotor functions gave speeches on themes related to the implementation of XPRIZE Healthspan clinical trials, after which participants from industry, government, and other sectors actively exchanged opinions.

The seminar speakers and themes are as follows:

Opening Remarks	Executive Vice President, Tohoku University and Director of Tohoku University Hospital　- Hideo Harigae *XPRIZE Healthspan Clinical Trial Director
Overview	About the Consortium for the Sendai-City × Tohoku University Smart-Frontier. Sendai-City Community Development Promotion Division Manager　- Suto Hayato
Lecture１	“Tohoku University’s Challenge to XPRIZE Healthspan: Towards the Development of Medicines for Longevity” Professor, Tohoku University Graduate School of Medicine　- Toshio Miyata（Director Chairman of the our Company） *XPRIZE Healthspan Tohoku University Team Representative
Lecture２	“Towards a Cognitive Assessment of XPRIZE Healthspan.” Tohoku University Smart-Aging Research Center Director and Professor, Institute of Development, Aging and Cancer　- Yasuyuki Taki *XPRIZE Healthspan Clinical Trial Manager (cognitive function)
Lecture３	“Effects of PA I-1 inhibitors on muscles and bones” Institute of Science Tokyo Hospital, Department of Orthopedic Surgery　- Yoshinori Asou *XPRIZE Healthspan Clinical Trial Manager (Muscle and Bone Function)
Lecture４	“Towards XPRIZE Healthspan Muscle Assessment” Professor, Sports and Health Sciences, Graduate School of Biomedical Engineering, Tohoku University　- Yosuke Yamada *XPRIZE Healthspan Clinical Trial Manager (Muscle Function)
Exchange of opinions	Comments from Council Members, exchange of opinions

¹⁾XPRIZE Healthspan is a global competition hosted by the XPrize Foundation that aims to revolutionize therapeutic approaches to human longevity and tackle the challenging task of actively extending healthy lifespan by 10 years or more. The XPrize Foundation will pay a total of US$100 million to the research team that can extend healthy lifespan by 2030. The XPRIZE Foundation is a non-profit private foundation in the United States, and Elon Musk and others are among its sponsors. The foundation has held several competitions with prize money aimed at developing technologies that benefit humanity and solving global challenges, such as the world’s first private lunar exploration and a competition for carbon dioxide (CO2) capture and storage technology.

²⁾Semi-final clinical trial of the XPRIZE Healthspan

A clinical study that evaluates the effects of short-term therapeutic intervention over 1-2 months on a small number of patients (up to 20 people) aged 50 or older. In addition to the effectiveness of the intervention, safety and subject protection measures, approval by the Certified Review Board (CRB), feasibility of patient registration, and ability to collect, manage, and submit data are evaluated comprehensively.

³⁾Final clinical trial of the XPRIZE Healthspan

A crossover clinical study that evaluates the effects of therapeutic intervention over a period of 4 years on approximately 100 people (up to 200 people) aged 50 or older. Compared to the control group, the intervention group must demonstrate at least 10 years of functional improvement in all three evaluation functions (muscles, cognition, and immunity).